What is the appropriate treatment for a 5 mm prolactin‑secreting pituitary microadenoma causing galactorrhea?

Treatment of 5 mm Prolactin-Secreting Microadenoma with Galactorrhea

Initiate cabergoline at 0.25–0.5 mg twice weekly on non-consecutive days (e.g., Monday and Thursday) as first-line therapy for this symptomatic microprolactinoma. 1

Rationale for Medical Therapy

• Dopamine agonist therapy is the definitive first-line treatment for symptomatic prolactin-secreting adenomas, regardless of size. 2
• Medical therapy is preferred over surgery for microadenomas because it normalizes prolactin in 92–95% of patients and resolves galactorrhea in approximately 86% of cases. 1, 2
• Cabergoline is superior to bromocriptine, achieving prolactin normalization in 92–95% of microadenomas versus only 68–80% with bromocriptine, while also being better tolerated. 1, 2

Dosing and Titration Protocol

• Start cabergoline at 0.25–0.5 mg twice weekly on non-consecutive days to minimize side effects while establishing efficacy. 1, 3
• Measure serum prolactin after 1 month of therapy to assess response. 1, 3
• If prolactin has not normalized, increase the dose by 0.25 mg increments every 4 weeks until prolactin falls below 25 ng/mL. 1, 3
• Most patients with microprolactinomas achieve control with a total weekly dose of 0.25–1 mg (e.g., 0.125–0.5 mg twice weekly). 3

Monitoring Strategy

• Perform monthly prolactin measurements during dose titration until stable normalization is achieved. 1, 3
• Once biochemical control is established, extend the monitoring interval based on clinical stability. 1
• Repeat pituitary MRI at 1 year after documented prolactin normalization to assess tumor response. 1, 2
• If prolactin rises unexpectedly or new symptoms develop (headache, visual changes, worsening galactorrhea), obtain MRI at 3 months. 1

Expected Outcomes

• Galactorrhea resolution occurs in approximately 86% of symptomatic patients. 2
• Prolactin normalization is achieved in 92–95% of microprolactinoma cases. 1, 2
• If the patient has amenorrhea, menstrual cycles normalize in 72–82% of previously amenorrheic women. 1, 2
• Tumor shrinkage of ≥50% occurs in 67–92% of treated prolactinomas, though this is less critical for a 5 mm lesion. 2

Duration of Therapy and Discontinuation

• After ≥2 years of continuous cabergoline with normalized prolactin and no residual tumor on MRI, the medication may be tapered and stopped with careful follow-up to detect recurrence. 1, 2
• Some guidelines suggest discontinuation may be considered after ≥6 months of sustained normal prolactin, though 2 years is the more conservative standard. 3

Alternative Management (Not Recommended for This Case)

• Observation without treatment is acceptable only for completely asymptomatic microprolactinomas, but galactorrhea is a clear indication for therapy. 1, 2
• Oral contraceptives may be offered to women with amenorrhea who do not desire pregnancy as an alternative to dopamine agonists, but they do not treat galactorrhea and are less costly with fewer side effects. 1, 2
• Transsphenoidal surgery should be reserved for patients who cannot tolerate or fail to respond to medical therapy; it is not first-line for microprolactinomas. 1, 4

Common Pitfalls to Avoid

• Do not use once-weekly dosing at treatment initiation; twice-weekly administration provides more stable prolactin suppression. 3
• Do not declare treatment failure prematurely; some patients require up to 6 months to achieve normoprolactinemia. 3, 2
• Do not stop cabergoline abruptly if pregnancy is confirmed; discontinue immediately upon pregnancy confirmation unless dealing with an invasive macroadenoma. 1
• Do not measure prolactin during pregnancy because physiologic elevation renders results uninterpretable. 1

Side Effect Profile

• Common mild adverse effects include nausea (27–29%), headache (26%), dizziness (15–17%), constipation (7–10%), and fatigue (10–18%). 3
• Severe adverse effects occur in approximately 7.7% of patients, with treatment withdrawal required in <1%. 3
• Rare but serious complications include cardiac valvulopathy and impulse-control disorders; baseline cardiovascular evaluation is recommended before initiating therapy. 3, 5